|1.||Maines, Lynn W: 2 articles (04/2010 - 04/2008)|
|2.||Zhuang, Yan: 2 articles (04/2010 - 04/2008)|
|3.||Smith, Charles D: 2 articles (04/2010 - 04/2008)|
|4.||Fitzpatrick, Leo R: 2 articles (04/2010 - 04/2008)|
|5.||Kelleher, D: 2 articles (02/2002 - 10/2001)|
|6.||Mahmud, N: 2 articles (02/2002 - 10/2001)|
|7.||Weir, D G: 2 articles (02/2002 - 10/2001)|
|8.||Li, Zhenjie: 1 article (11/2015)|
|9.||Liu, Hongyan: 1 article (11/2015)|
|10.||Peng, Haiying: 1 article (11/2015)|
09/01/1994 - "The optimal dose of olsalazine for maintaining remission in ulcerative colitis is 1 g/day. "
12/01/2008 - "acidophilus probiotic could be recommended as adjuvant therapy in combination with olsalazine to achieve more effective treatment for ulcerative colitis. "
09/01/1994 - "To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. "
01/01/1995 - ": Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. "
06/01/1992 - "Olsalazine is also effective in the maintenance of remission of ulcerative colitis. "
01/01/1988 - "Statistically significant or nearly significant improvement was demonstrated in colitis activity by the end compared to the beginning of the study within the combined olsalazine group and within patient groups receiving olsalazine at daily doses of 1.5 g and 3 g. "
12/01/1987 - "When the colitis activity at study entry was compared with that observed at the completion of the study period, statistically significant or nearly significant improvement was demonstrated within the combined olsalazine group (p = 0.01) and within patient groups receiving olsalazine at daily doses of 1.5 g (p = 0.04) and 3 g (p = 0.055). "
05/01/2010 - "normal control group (G1), untreated TNBS-induced colitis (G2), TNBS-induced colitis treated with live combined bifidobacterium, lactobacillus and enterococcus (G3), TNBS-induced colitis treated with olsalazine (G4) and TNBS-induced colitis treated with both live combined bifidobacterium, lactobacillus and enterococcus and olsalazine at the same dose and duration (G5). "
01/01/1992 - "Experimental colitis in mice: effects of olsalazine on eicosanoid production in colonic tissue."
01/01/1988 - "Olsalazine is a new drug for the treatment of ulcerative and Crohn's colitis. "
|3.||Crohn Disease (Crohn's Disease)
01/01/1995 - "This study was unable to show that patients with mild to moderate attacks of Crohn's disease were significantly improved by treatment with olsalazine at a dose of 1 g daily. "
05/01/2002 - "Olsalazine was not better than placebo in maintaining remission in inactive Crohn disease."
01/01/1995 - "A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease."
10/01/2001 - "Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study."
10/01/2001 - "The primary aim of this study was to evaluate the prophylactic properties of olsalazine in comparison with placebo for maintenance of remission in quiescent Crohn's colitis and/or ileocolitis. "
|4.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
11/01/1994 - "Her inflammatory bowel disease (IBD) remained controlled and she did not develop a recurrence of lupus, suggesting that olsalazine is safe in patients with IBD and a history of SSZ induced lupus. "
06/01/1994 - "Treatment of inflammatory bowel disease with olsalazine causes diarrhoea in 10% of patients. "
06/01/1992 - "The history, pharmacology, pharmacokinetics, clinical uses and efficacy, adverse effects, drug interactions, and dosage and administration of rectal mesalamine and oral olsalazine in the treatment of inflammatory bowel disease (IBD) are reviewed. "
06/01/1992 - "Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease."
07/01/1990 - "olsalazine and mesalazine) have been developed for the treatment of chronic inflammatory bowel diseases. "
05/01/1990 - "Overall, of 14 patients treated with Olsalazine, nine (64%) improved, one showed no improvement, and four (29%) discontinued because of persistent watery diarrhea. "
05/01/1990 - "Of the seven patients randomized to olsalazine, four (57%) improved clinically and by colonoscopic scoring, one showed no improvement in either, and two (29%) withdrew after developing severe watery diarrhea. "
05/01/1996 - "The study was closed early, after entry of 58 evaluable patients, when a preliminary analysis showed excessive diarrhea in patients randomized to olsalazine. "
10/01/1993 - "In patients who did not develop diarrhea, olsalazine was well tolerated and successfully prevented rapid relapse in the recently ill patients entered into this study."
10/01/1993 - "The most important side effect experienced with olsalazine that necessitated withdrawal from the study was "drug-induced diarrhea" in 16% (8/49). "
|4.||methylmethacrylate-methacrylic acid copolymer
|9.||Adrenal Cortex Hormones (Corticosteroids)